INMED PHARMACEUTICALS INC. Net Fee Amt
INMED PHARMACEUTICALS INC. (INM) had Net Fee Amt of $0.61 as of 2026-09-09, per its S-4/A filed 2026-09-09.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-09-09
- 2026-09-09: Net Fee Amt $0.61.
- 2026-07-02: Net Fee Amt $2.08.
| Period end | Net Fee Amt |
|---|---|
| 2026-09-09 | $0.61 S-4/A · filed 2026-09-09 |
| 2026-07-02 | $2.08 S-4 · filed 2026-07-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |